Human MOG組換え体(リコンビナント)タンパク質 | Recombinant Human MOG

R&D Systems社製の高品質なHuman MOGの組換え体タンパク質(Recombinant Human MOG)です。

※本製品は研究用です。研究用以外には使用できません。

※バルク包装品も承ります。お気軽にお問合せ下さい。

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

Myelin oligodendrocyte glycoprotein (MOG) is 28 kDa single-pass transmembrane glycoprotein that is a member of the Ig superfamily (1, 2). Human MOG is synthesized with a 29 amino acid (aa) signal sequence, a 125 aa extracellular domain (ECD) containing an Ig-like domain, a 21 aa transmembrane domain, and a 72 aa cytosolic fragment featuring a hydrophobic domain that associates with the cytoplasmic face of the plasma membrane. The ECD of mature human MOG shares 90% aa sequence identity with the ECD of both mouse and rat MOG. Unlike mouse and rat, human MOG has seven splice variants, including a soluble ECD isoform and multiple isoforms that have a truncated cytoplasmic domain (3, 4). Dimerization of MOG occurs via the extracellular Ig-like domain (5-8). MOG is expressed exclusively by oligodendrocytes in the central nervous system (CNS) and is localized to the outer layer of the myelin sheath as well as in the oligodendrocyte plasma membrane (9). MOG expression in the brain can be used as a temporal biomarker for myelin development. MOG is an important antigenic target for autoimmune diseases that mediate demyelination in the CNS (10). In vivo administration of exogenous MOG protein or peptide induces experimental autoimmune encephalomyelitis (EAE) in multiple animal species (11, 12). EAE is used as an animal model for multiple sclerosis and related CNS demyelinating diseases. MOG is thought to function as an adhesion molecule as well as a mediator of immune activation in the CNS (9, 13).